Redx Pharma is a UK-based clinical stage drug discovery company that specialises in developing highly targeted small molecules based on its proven medicinal chemistry expertise and research platform discovery engine. These are either “best-in-class” or “first-in-class” and target existing unmet needs in selected oncology and fibrosis indications. A driven management team is implementing a focussed and ambitious strategy which should transform the business over the medium term. This approach has been validated by a series of out-licensing and partnering deals. Knowledgeable and supportive shareholders have rebuilt the balance sheet, but further funding is required to capitalise on the existing opportunities. Our valuation, based on conservative assumptions, is £434m, equivalent to 157.5p/share.
17 Feb 2022
Redx Pharma: Building on an impressive track-record
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Redx Pharma: Building on an impressive track-record
Redx Pharma Plc (REDX:LON), 11.8 | Redx Pharma Plc (REDX:LON), 11.8
- Published:
17 Feb 2022 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
32
Redx Pharma is a UK-based clinical stage drug discovery company that specialises in developing highly targeted small molecules based on its proven medicinal chemistry expertise and research platform discovery engine. These are either “best-in-class” or “first-in-class” and target existing unmet needs in selected oncology and fibrosis indications. A driven management team is implementing a focussed and ambitious strategy which should transform the business over the medium term. This approach has been validated by a series of out-licensing and partnering deals. Knowledgeable and supportive shareholders have rebuilt the balance sheet, but further funding is required to capitalise on the existing opportunities. Our valuation, based on conservative assumptions, is £434m, equivalent to 157.5p/share.